<DOC>
	<DOC>NCT00406640</DOC>
	<brief_summary>Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major depressive disorder (MDD) who are postmenopausal.</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Postmenopausal women between the ages of 40 and 70 years, inclusive. A primary diagnosis of MDD, single or recurrent episode, without psychotic features using the modified MINI International Neuropsychiatric Interview (MINI). MontgomeryAsberg Depression Rating Scale (MADRS) total score &gt; or = 22 at the screening and baseline visit. Use of oral estrogen, progestin, androgen, or Selective Estrogen Receptor Modulator (SERM)containing drug products 8 weeks before baseline. Current (within 12 months) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessivecompulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder. A history or active presence of clinically important medical disease. Additional criteria apply.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>MDD</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
</DOC>